The presence of diabetes is clearly associated with excess cardiovascular risk. 1 However, much controversy exists over whether current glucose-lowering strategies in type 2 diabetes mellitus in fact reduce cardiovascular event rates. Older data had suggested that lowering blood glucose reduced ischaemic events, but contemporary trials of relatively short duration have challenged the long-held concept that more intense glycaemic control reduces macrovascular events in type 2 diabetes mellitus, with some studies even suggesting a potential hazard of excessive lowering of haemoglobin A 1c (HbA 1c ) . 2 -5 Meta-analyses had previously supported that long-term glucose lowering was associated with a modest reduction in adverse cardiovascular outcomes. 6, 7 Perhaps, then, the key is safe lowering of glucose over a period of time that exceeds typical clinical trial durations. Ross et al. have now published what will become a classic paper in the field of diabetes and cardiovascular risk. 8 Using the powerful technique of Mendelian randomization, these authors show that a lifetime of lower glucose levels is indeed associated with a lower risk of adverse cardiovascular outcomes. Particular genetic variants-known as single nucleotide polymorphisms (SNPs)-which have been associated with diabetes, HbA 1c levels, and fasting glucose were examined. The causal effect of diabetes on the risk of coronary artery disease (CAD) was estimated at an odds ratio (OR) of 1.57 (P ¼ 0.008) and, importantly, per 1% increase, the HbA 1c was associated with an OR of 1.53 (P ¼ 0.023) in the risk of CAD. Somewhat surprisingly, SNPs associated with fasting glucose levels were not significantly associated with CAD risk (though the analysis had very limited statistical power for this particular variable, so this null finding should be interpreted with caution). The authors carefully adjusted for genetic effects of the diabetesassociated SNPs under study on other cardiovascular risk factors such as hypercholesterolaemia, hypertension, and obesity; without this step, a direct independent effect of diabetes on cardiac risk could not be assumed. With adjustment for lipids and body mass index, which previous studies of diabetes had not done as elegantly, 9 the SNPs associated with diabetes remained significantly associated with CAD (OR 1.63, P ¼ 0.002), though the association with HbA 1c was no longer statistically significant (but was still directionally consistent). Not all potential confounders were available for adjustment. For example, smoking and waist-to-hip ratio were not incorporated, as the authors acknowledge among the limitations of this analysis. Also, it is worth mentioning that the patients included were largely of European ancestry, so similar analyses in other racial and ethnic groups would be of added value. It is noteworthy that in the current study the degree of risk associated with diabetes is similar to what has been noted in prior observational analyses and meta-analyses, though with different populations and statistical techniques. 1, 7 It is comforting and reassuring to see so many different lines of evidence converging in support of diabetes and elevated levels of glycaemia being causally associated with CAD. Several other points about this analysis deserve mention. The use of Mendelian randomization essentially replicates a randomized double-blind clinical trial, with nature serving as the ultimate randomizer. These types of studies also allow the follow-up period to be essentially life-long, far surpassing what can be practically done in most randomized clinical trials. The genetic biobank data utilized in this study were freely available, thus allowing a very costeffective and efficient method to address a hypothesis. Whether specific lifestyle, medical, or surgical approaches to improving glycaemic control provide similar benefit to genetically influenced glucose levels would need to be proved, but this supposition appears likely if hypoglycaemia or other potential side effects do not create counterbalancing effects. 10, 11 Interestingly, in the analysis by Ross et al., there were no significant differences according to whether the effect of the genetic loci was on beta-cell function or insulin resistance. This finding provides strong indirect evidence
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that the exact mechanism of glucose lowering may not matter, again assuming it can be accomplished safely. Questions that the current study design could not answer include whether the relationship between HbA 1c and cardiovascular risk is linear or non-linear. That is, would the excess risk conferred by moving from an HbA 1c of 7% to 8% be similar to moving from 8% to 9%. That knowledge would be important from a therapeutic standpoint in terms of thresholds at which to initiate treatment and also to determine HbA 1c targets. However, since these authors lacked individual level data, they could not perform that type of analysis, but potentially it could be done in the future.
The study by Ross and colleagues further reinforces the value of Mendelian randomization studies to elucidate what risk factors are truly causal as opposed to being merely associative. Mendelian randomization is a powerful example of instrumental variable analysis that, when done properly, largely circumvents the confounding and reverse causation that often plagues observational analyses. Prior Mendelian randomization work has shown that LDL-cholesterol is on the causal pathway towards development of CAD. More recently, inactivating mutations of Niemann -Pick C1-like 1 (NPC1L1) protein have been associated with lower cardiovascular risk. 12 The value of this genetic study was confirmed in a large randomized clinical trial that subsequently demonstrated the ability of ezetimibe (which inhibits the activity of NPC1L1 protein) to reduce the risk of ischaemic events. Mendelian randomization studies showed that triglycerides (or more specifically their associated apolipoproteins) are also on the causal pathway for CAD, and large cardiovascular outcome studies are underway. 13 In contradistinction, the HDLassociated SNPs studied to date do not support a causal role for HDL-cholesterol in CAD. 14 The negative clinical trials of HDL-raising drugs confirm that lack of causality. Now, the present study by Ross and colleagues extends these previous observations regarding other putative cardiac risk factors and the relationship to CAD risk to diabetes and HbA 1c , demonstrating that better glycaemic control (when achieved naturally through genetic determinants) does correlate with lower cardiovascular risk ( Figure 1 ). As such, this paper by Ross et al. is a major contribution to the field of diabetes and cardiovascular prevention and strongly supports ongoing efforts to lower HbA 1c through lifestyle, pharmacological, and surgical means while awaiting randomized clinical trials that validate specific approaches to reduce cardiovascular event rates. 
